ClinicalTrials.gg
Active, not recruitingNCT06824181Updated Feb 13, 2026

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

A Phase 3 interventional study of PCV21 vaccine and Prevnar 20 vaccine in Pneumococcal Immunization, sponsored by Sanofi. Active, not recruiting at 27 sites in 4 countries. Open to participants aged 42 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
580
Allocation
Randomized
Ages
42 Days to 89 Days
Sex
All
01

Study summary

This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days).

The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age (MoA). Routine pediatric vaccines will be given as per local recommendations.

There will be 6 study visits:

Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.

02

Conditions studied

  • Pneumococcal Immunization
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 89 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 42 to 89 days on the day of inclusion
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination
  • Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg or born after a gestation period above 28 (> 28 weeks) through 36 weeks with a birth weight ≥ 1.5 kg, and in both cases medically stable as assessed by the investigator

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic therapy
  • History of microbiologically confirmed Streptococcus pneumoniae infection or disease.
  • History of seizure or significant stable or progressive neurologic disorders such as inflammatory nervous system diseases, encephalopathy, cerebral palsy
  • Known systemic to any of the study interventions components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
  • Thrombocytopenia, or known thrombocytopenia, as reported by the parent/legal acceptable representative (LAR), contraindicating intramuscular (IM) injection.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Previous vaccination against Streptococcus pneumoniae
  • Receipt of immune globulins, blood or blood-derived products since birth
  • Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
580 participants (actual)

Study arms

  • Experimental
    Group 1: 20vPCV-PCV21-PCV21-PCV21

    Participants will be administered via intramuscular injection (IM) a 4-dose 20vPCV regimen at approximately 2 MoA, PCV21 at 4 MoA, PCV21 at 6 MoA and PCV21 at 12 to 15 MoA

    Biological: PCV21 vaccine · Biological: Prevnar 20 vaccine · Biological: M-M-R II vaccine · Biological: Rotarix · Biological: RotaTeq · Biological: Vaxelis vaccine · Biological: Varivax · Biological: Priorix · Biological: VAQTA · Biological: Havrix

  • Experimental
    Group 2: 20vPCV-20vPCV-PCV21-PCV21

    Participants will be administered via intramuscular injection (IM) a 4-dose 20vPCV regimen at approximately 2 MoA, 20vPCV at 4 MoA, PCV21 at 6 MoA and PCV21 at 12 to 15 MoA

    Biological: PCV21 vaccine · Biological: Prevnar 20 vaccine · Biological: M-M-R II vaccine · Biological: Rotarix · Biological: RotaTeq · Biological: Vaxelis vaccine · Biological: Varivax · Biological: Priorix · Biological: VAQTA · Biological: Havrix

  • Experimental
    20vPCV-20vPCV-20vPCV-PCV21

    Participants will be administered via intramuscular injection (IM) a 4-dose 20vPCV regimen at approximately 2 MoA, 20vPCV at 4 MoA, 20vPCV at 6 MoA and PCV21 at 12 to 15 MoA

    Biological: PCV21 vaccine · Biological: Prevnar 20 vaccine · Biological: M-M-R II vaccine · Biological: Rotarix · Biological: RotaTeq · Biological: Vaxelis vaccine · Biological: Varivax · Biological: Priorix · Biological: VAQTA · Biological: Havrix

  • Active comparator
    20vPCV-20vPCV-20vPCV-20vPCV

    Participants will be administered via intramuscular injection (IM) a 4-dose 20vPCV regimen at approximately 2 MoA, 20vPCV at 4 MoA, 20vPCV at 6 MoA and 20vPCV at 12 to 15 MoA

    Biological: Prevnar 20 vaccine · Biological: M-M-R II vaccine · Biological: Rotarix · Biological: RotaTeq · Biological: Vaxelis vaccine · Biological: Varivax · Biological: Priorix · Biological: VAQTA · Biological: Havrix

Interventions

  • BiologicalPCV21 vaccine

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

    Also known as: 515

  • Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

    Also known as: Prevnar20™

  • Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular

    Also known as: M-M-R™ II

  • BiologicalRotarix

    Pharmaceutical form:Solution-Route of administration:Oral

    Also known as: Rotarix™

  • BiologicalRotaTeq

    Pharmaceutical form:Solution-Route of administration:Oral

    Also known as: RotaTeq™

  • BiologicalVaxelis vaccine

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

    Also known as: Vaxelis™

  • BiologicalVarivax

    Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular

    Also known as: Varivax™

  • BiologicalPriorix

    Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous

    Also known as: Priorix™

  • BiologicalVAQTA

    Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular

    Also known as: VAQTA™

  • BiologicalHavrix

    Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular

    Also known as: Havrix™

06

What researchers measure

Primary outcomes

  1. Presence of any immediate adverse events (AEs)

    Number of participants experiencing solicited and unsolicited immediate AEs

    Time frame: Within 30 minutes after each vaccination

  2. Presence of solicited injection site and systemic reactions through 7 days after each vaccine injection

    Number of participants experiencing solicited injection site and systemic reactions

    Time frame: Through 7 days after each vaccine injection

  3. Presence of unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs through 30 days after each vaccine injection

    Number of participants experiencing unsolicited injection site reactions and unsolicited systemic AEs

    Time frame: Through 30 days after each vaccine injection

  4. Presence of serious adverse events (SAEs) throughout the study (through 6 months post- last vaccine injection)

    Number of participants experiencing SAEs

    Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 19 months

  5. Presence adverse events of special interest (AESIs) throughout the study (through 6 months post- last vaccine injection)

    Number of participants experiencing AESIs

    Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 19 months

  6. Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days PD4

    The GMCs for serotype-specific pneumococcal IgG antibodies are measured using electro-chemiluminescence assay (ECL)

    Time frame: 30 days PD4

07

Study locations

27 sites
  • Kaiser Permanente - Los Angeles Medical Center- Site Number : 8400025
    Los Angeles, California 90027, United States
  • The Medici Medical Research- Site Number : 8400008
    Hollywood, Florida 33021, United States
  • Clinsearch Inc at Dr. Gala, LLC- Site Number : 8400027
    Miami, Florida 33135, United States
  • Atlantis Clinical Research- Site Number : 8400009
    Miami, Florida 33173, United States
  • Velocity Clinical Research - Sioux City- Site Number : 8400007
    Sioux City, Iowa 51106, United States
  • Private Practice - Dr. Michael W. Simon- Site Number : 8400001
    Lexington, Kentucky 40517, United States
  • Velocity Clinical Research - New Orleans- Site Number : 8400006
    New Orleans, Louisiana 70119, United States
  • Finger Lakes Medical Research - Cortland- Site Number : 8400022
    Cortland, New York 13045, United States
  • University of Rochester Medical Center- Site Number : 8400019
    Rochester, New York 14642, United States
  • SUNY Upstate Medical University - Syracuse- Site Number : 8400015
    Syracuse, New York 13210, United States
  • Kid's Way Pediatrics- Site Number : 8400013
    Hermitage, Pennsylvania 16148, United States
  • Carolina Family Care - Charleston- Site Number : 8400014
    Charleston, South Carolina 29414, United States
  • Helios Clinical Research - BUR PEDI- Site Number : 8400016
    Burleson, Texas 76028, United States
  • Clinsearch Inc at VAST Clinical Research- Site Number : 8400028
    Euless, Texas 76040, United States
  • DM Clinical Research - Houston - Jones Road- Site Number : 8400012
    Houston, Texas 77065, United States
  • University of Texas Medical Branch at Galveston- Site Number : 8400005
    League City, Texas 77555, United States
  • Javara - Privia Medical Group North Texas - Stephenville- Site Number : 8400024
    Stephenville, Texas 76401, United States
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 8330034, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 8380418, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 8880465, Chile
  • Investigational Site Number : 4840003
    León, Guanajuato 37320, Mexico
  • Investigational Site Number : 4840001
    Mexico City, Mexico City 04530, Mexico
  • Investigational Site Number : 4840002
    Temixco, Morelos 62587, Mexico
  • Investigational Site Number : 4840004
    Tlaltizapán, Morelos 62770, Mexico
  • Investigational Site Number : 6080001
    Cebu City, 6000, Philippines
  • Investigational Site Number : 6080002
    Quezon City, 1100, Philippines
  • Investigational Site Number : 6080003
    Quezon City, 1121, Philippines
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Sep 2027, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 13, 2025
StartActual
Feb 27, 2025
Primary completionEst.
Sep 10, 2027
CompletionEst.
Sep 10, 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06824181
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Feb 27, 2025
Primary completion
Sep 10, 2027 (estimated)
Completion
Sep 10, 2027 (estimated)
Last update
Feb 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion